The Pulse: Breaking News from the Life Sciences Sector

Source:

biotek1To invest wisely in the life sciences, broad-spectrum knowledge is key. Such knowledge encompasses not only the analysis of industry experts featured in Streetwise Reports interviews, but also up-to-date news on cutting-edge research and development, the latest mergers and acquisitions and the drug development process, both within companies and in the regulatory arena. Our Twitter feed links you to the information you need to profit, both intellectually and financially.

Supreme Court Ensures Funding of Research Using Human Embryonic Stem Cells
Embryonic stem cell researchers were reported to be "jubilant" after the U.S. Supreme Court refused to consider a case that would have blocked National Institutes of Health research using the cells. The case was brought by two adult stem cell researchers seeking to "to emancipate human embryos from research slavery sponsored by the NIH."

M&A Buzz: Pharma Deals Worth North of $1B May Return in 2013
Pharmaceutical companies including Pfizer Inc. and Bristol-Myers Squibb Co. have spent the last several years digesting earlier acquisitions, refocusing product development and setting aside cash in anticipation of expiring patents. Now, the expectation is they're are ready to start buying again.

7 Biotech Trends for the Coming Year
What does 2013 hold for the biotech industry? America didn't fall off the fiscal cliff when the clock struck midnight on New Year's Eve, yet 2013 still presents numerous challenges for the biopharma industry to overcome. Genetic Engineering and Biotechnology News has compiled a list of some key biopharma developments likely to shape the coming 12 months.

Planning a big night out? Eating asparagus could prevent that nasty hangover
Drinking milk, eating bread, water before bed; the list of hangover prevention methods is extensive. However, new research suggests that tucking into a few asparagus shoots before a big night out may be all that is required.

Genentech's cancer-fighting T-DM1 leads the FDA's Class of 2013
T-DM1's chances for earlier-than-expected approval rest in the fact that a lot is already known about one piece of the so-called antibody-drug conjugate. T-DM1 couples Genentech's blockbuster cancer drug Herceptin with a chemotherapy agent developed by ImmunoGen Inc.

Top 5 New Year's resolutions for the medical device industry include passing the comparative effectiveness test
Selling to physicians and being paid on the basis of how many widgets sold is so 20th century. The new world order demands evidence of how well a medical device works and whether it reduces the cost of care. Industry leaders have to figure out where their products fit in a system where wellness is a priority.

An investor's guide: Four ways to survive the Series A crunch
It's almost 2013, and many seed-funded companies are hoping the New Year will yield a big, fat Series A check. But there is a "seed cliff" that is showing no signs of letting up.

To read the latest Life Sciences Report interview click here.

Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe